SLC25A38

Across TCGA pan-cancer cohorts, SLC25A38 Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated SLC25A38 data layer compared with 20 for mass-spec protein.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where higher SLC25A38 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated SLC25A38 expression acts as an unfavorable survival marker.

LIHC, STAD, and UCEC are the cancer types where SLC25A38 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LIHC	OS	Median	All	0.033	0.784	<.001	24	view →
STAD	OS	Median	II,III,IV	0.164	0.663	.001	12	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

SLC25A38–LIHC (OS)

Open the LIHC breakdown →